NCT03205657

Auto/Allo Tandem Transplant for Relapsed B-NHL

MAC and autoHSCT, Targeted Immunotherapy and RIC alloHSCT in Children, Adolescents, and Young Adults (CAYA) With Poor-risk Refractory/Relapsed Mature B-NHL: A Retrospective Chart Review

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 12 (actual)
• Sponsor: New York Medical College · Academic / Other
• Sex: All
• Age: 0 Years – 29 Years
• Healthy volunteers: —

Summary

The investigators plan to perform a retrospective review of patients with poor risk relapsed/refractory B-NHL having received HSCT and targeted immunotherapy at the Maria Fareri Children's Hospital between January 1, 2012 and June 1, 2015. The investigators will review the clinical records and collect the data with de-identified medical information from our HSCT clinical research database.

Detailed description

The investigators will obtain the following information from the patient's medical records: clinical factors including age at presentation, gender, clinical presentation, laboratory and pathology data, lymphoma diagnosis, clinical staging criteria, anti-cancer therapy as well as supportive care medicines, complications of therapy (adverse events graded from CTCAE v4.0), and hematopoietic stem cell transplantation therapy (chemotherapy, donor source, cell dose), course (engraftment, GVHD, chimerism), and follow-up (disease status).

Conditions

• Non Hodgkin Lymphoma

Interventions

Type	Name	Description
PROCEDURE	auto transplant followed by allo transplant	patients who got MAC conditioning with auto SCT followed by RIC followed by alloSCT for mature B-NHL

Timeline

• Start date: 2016-06-01
• Primary completion: 2021-12-31
• Completion: 2022-08-31
• First posted: 2017-07-02
• Last updated: 2023-11-07